The Company’s exports for the quarter amounted to Rs.144.96 crores (Rs.116.33 crores) registering a growth of 24.61% over the corresponding period.  Domestic sales in the first quarter grew by 22.92% to Rs.160.91 crores, inspite of adverse environment due to transport strike and vat associated trade issues.

Aurobindo has invested vast resources to transform into a vertically integrated global generics company by creating a powerful infrastructure in R&D, manufacturing and regulatory affairs of API’s and formulations.  The three API hubs with several blocks dedicated to regulatory markets and three formulation hubs in India in addition to the facility at California, USA are geared up for approvals from regulated markets with support from the R&D center employing over 250 scientists dedicated to global generics business.  Consequent to the above structural changes, the staff costs and depreciation costs have increased to Rs.11.15 crores (Rs.5.89 crores) and Rs.7.07 crores (Rs.3.93 crores) respectively.   Aurobindo is developing a robust and broad product portfolio comprising niche products, large volume products and Para 4 based products for a successful presence in regulated markets from year 2004 onwards.  The R&D has obtained select process patents and filed several patents in regulated markets to enable a profitable entry into global generics business.

The efforts to capture higher market share in semi regulated markets through deeper penetration strategies in China, Brazil, Latin American countries and the rest of the world have started yielding good results for a robust growth rate in exports.  Two mega manufacturing API hubs created subsequent to restructuring are supporting the semi regulated markets business.

Domestic branded formulations business of Citadel Aurobindo Biotech Ltd., the company’s joint venture is now fully operational and the sales are growing rapidly which are expected to cross a land mark figure of Rs.100 crores during the current financial year.